Ophthalmology · Waltham, MA
NPI
1801107859
Since 2010
Specialty
Ophthalmology
Code 207W00000X
Group practices
3
Medicare group memberships
Hospitals
1
Hospital affiliations
1440 Main St, Ste 201
Waltham, MA, 02451
Phone (781) 891-6377
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.2M
36,461 services
Medicare patients, 2024
1,024
Average age 75
Drug cost, 2024
$5.1M
2,367 prescriptions
Company payments, 2025
$201K
From 22 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Peter Y Chang was code J2777 (injection, faricimab-svoa, 0.1 mg), 12,180 times for 51 patients. In total Peter Y Chang billed 36,461 services in 99 codes, and Medicare paid $2.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-25.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J2777 Injection, faricimab-svoa, 0.1 mg | Office | 12,180 | 51 | $27.50 | $335K |
| J2403 Chloroprocaine hcl ophthalmic, 3% gel, 1 mg | Office | 9,601 | 11 | $0.51 | $4,937 |
| J0177 Injection, aflibercept hd, 1 mg | Office | 2,546 | 84 | $264.29 | $673K |
| 92134 Computerized Ophthalmic Imaging | Office | 1,382 | 704 | $35.16 | $49K |
| 92014 Ophthalmological E&M | Office | 1,216 | 679 | $108.71 | $132K |
| 67028 Intravitreal Injection | Office | 670 | 185 | $115.18 | $77K |
| J3299 Injection, triamcinolone acetonide (xipere), 1 mg | Office | 508 | 13 | $37.83 | $19K |
| 99214 Office E&M - Established | Office | 289 | 122 | $108.58 | $31K |
| 92012 Ophthalmological E&M | Office | 266 | 216 | $70.37 | $19K |
| J0178 Injection, aflibercept, 1 mg | Office | 262 | 58 | $664.77 | $174K |
| 92136 Ultrasound - Nonspecific | Office | 217 | 111 | $20.62 | $4,475 |
| 84450 Clinical Chemistry | Office | 205 | 64 | $5.08 | $1,041 |
| 84520 Clinical Chemistry | Office | 205 | 64 | $3.87 | $793 |
| 85025 Blood Count | Office | 205 | 64 | $7.61 | $1,560 |
| 82565 Clinical Chemistry | Office | 205 | 64 | $5.02 | $1,029 |
By year: 2022 $1.5M for 11,469 services; 2023 $1.5M for 19,333 services; 2024 $2.2M for 36,461 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 84460 Clinical Chemistry | 205 | 64 | $5.19 | $1,064 |
| 84520 Clinical Chemistry | 205 | 64 | $3.87 | $793 |
| 82565 Clinical Chemistry | 205 | 64 | $5.02 | $1,029 |
| 85025 Blood Count | 205 | 64 | $7.61 | $1,560 |
| 84450 Clinical Chemistry | 205 | 64 | $5.08 | $1,041 |
| 82977 Clinical Chemistry | 204 | 64 | $7.06 | $1,440 |
| 82947 Clinical Chemistry | 204 | 64 | $3.85 | $785 |
| 36415 Venipuncture Blood Collection | 179 | 56 | $8.65 | $1,548 |
| 88350 Immunohistochemistry | 80 | 15 | $112.56 | $9,005 |
| 88341 Immunohistochemistry | 70 | 13 | $89.14 | $6,240 |
Medicare prescription drug claims, 2024
In 2024, the drug Peter Y Chang prescribed most often to Medicare patients was Dorzolamide-Timolol (Dorzolamide Hcl/Timolol Maleat), with 171 prescriptions and refills. In total Peter Y Chang wrote 2,367 Medicare prescriptions that cost $5.1M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Dorzolamide-Timolol Dorzolamide Hcl/Timolol Maleat | 171 | 378 | 58 | $2,612 |
| Prednisolone Acetate Generic | 156 | 215 | 85 | $7,070 |
| Brimonidine Tartrate Generic | 150 | 304 | 47 | $9,785 |
| Methotrexate Methotrexate Sodium | 133 | 279 | 37 | $3,818 |
| Timolol Maleate Generic | 130 | 270 | 41 | $1,201 |
| Latanoprost Generic | 104 | 248 | 42 | $1,198 |
| Mycophenolate Mofetil Generic | 80 | 185 | 24 | $19K |
| Valacyclovir Valacyclovir Hcl | 73 | 170 | 23 | $4,998 |
| Doxycycline Hyclate Generic | 69 | 88 | 25 | $2,769 |
| Neomycin-Polymyxin-Dexameth Neomycin/Polymyxin B/Dexametha | 65 | 70 | 35 | $536 |
| Bromfenac Sodium Generic | 63 | 104 | 24 | $22K |
| Humira(Cf) Pen Adalimumab | 55 | 57 | Under 11 | $400K |
| Dorzolamide Hcl Generic | 53 | 103 | 22 | $1,013 |
| Ketorolac Tromethamine Generic | 52 | 80 | 19 | $622 |
| Oxervate Cenegermin-Bkbj | 48 | 48 | 13 | $1.5M |
Brand drugs: 844 claims; generic drugs: 1,523 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Peter Y Chang $201K ($201K in general payments such as food, travel and fees) from 22 companies. The largest payer was Mallinckrodt Hospital Products Inc. with $110K.
| Company | Payments | Amount |
|---|---|---|
| Mallinckrodt Hospital Products Inc. | 107 | $110K |
| Regeneron Healthcare Solutions, Inc. REGN | 27 | $48K |
| ANI Pharmaceuticals, Inc. ANIP | 27 | $20K |
| Astellas Pharma US Inc 4503.T | 7 | $7,008 |
| X4 Pharmaceuticals, Inc. XFOR | 1 | $6,000 |
| Bausch & Lomb Americas Inc. BLCO | 10 | $5,899 |
| Genentech, Inc. ROG.SW | 2 | $1,680 |
| Abbvie Inc. ABBV | 27 | $706 |
| Samsara Vision | 3 | $415 |
| Tarsus Pharmaceuticals, Inc. TARS | 5 | $259 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.